Cases
ArcanaBio establishes itself in Copenhagen
Dec 17, 2024 The Icelandic biotechnology company, ArcanaBio, has selected Copenhagen as its new strategic hub for expansion in the Nordics and the rest of Europe. With support from Copenhagen Capacity, ArcanaBio will establish an office and research facilities in the city — a significant step in the company’s international expansion and growth strategy.With ArcanaBio’s arrival, Denmark gains access to the biotechnology of the future, strenghtening the region as the hub for advanced biotech. The company is renowned for its advanced biotech solutions in gene sequencing, molecular diagnostics, and personalized medicine. Headquartered in Reykjavik, ArcanaBio has established itself as a pioneer in the application of cutting-edge technologies to improve the healthcare sector. The new base in Copenhagen strengthens ArcanaBio's mission to drive innovation and collaboration within one of Europe’s most dynamic biotech ecosystems.
“Copenhagen is a natural choice for us. The city offers a unique combination of talent, world-class research, and a strong business environment. With help from Copenhagen Capacity, we have found the perfect platform to strengthen our network and accelerate our research and development,” says Kristjan Gunnarsson, CEO and Founder of ArcanaBio.
Copenhagen Capacity helps the company setting up their business in Copenhagen
Copenhagen Capacity played a key role in the decision-making and establishment process prior to ArcanaBio’s arrival in Copenhagen. The organization provided strategic advice, facilitated connections with local partners, and offered guidance on navigating Danish business regulations.
“We are proud to have contributed to attracting such an innovative company as ArcanaBio to Copenhagen. The city is already at the forefront of research into the latest forms of diagnostics and personalized medicine, so it is only natural for international expertise to be drawn here and strengthen our position even further. This confirms the region’s strength as a global center for biotechnology and life sciences,” says Asbjørn Overgaard, CEO of Copenhagen Capacity.
ArcanaBio’s presence is expected to create new opportunities for collaboration with Danish universities, hospitals, and companies. The investment will also support the creation of new jobs and contribute to Denmark's position as a global leader in biotechnology and health innovation.
